APA: Novel Antipsychotic Promising for Schizophrenia (CME/CE)
SAN FRANCISCO (MedPage Today) — The experimental psychotropic agent lurasidone appeared effective in acute schizophrenia, according to the first phase III data on the drug.
Similar Posts on depression:
- APA: Inhaled Agent Loxapine Effective in Acute Agitation (CME/CE)
- FDA Review Questions Cardiac, Suicide Risks for Investigational Antipsychotic
- FDA Review Questions Cardiac, Suicide Risks for Investigational Antipsychotic
- APA: Psychiatrist-Pharma Relationships Need Clearer Boundaries
- APA: Nicotine Patch May Soothe Schizophrenic Smokers (CME/CE)
- Substance Abuse May Account for Most Violent Acts in Schizophrenia (CME/CE, with audio)
- APA: Depression Linked to Obesity Mainly in Women (CME/CE, with video)
- FDA Approves Iloperidone for Schizophrenia
- APA: DSM Revision on Track for 2012 Release
- Low-Dose Naltrexone Eases Pain and Fatigue of Fibromyalgia
